Söndag 22 December | 05:07:12 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-10-22 07:00 Kvartalsrapport 2025-Q3
2025-07-11 07:00 Kvartalsrapport 2025-Q2
2025-04-29 N/A Årsstämma
2025-04-29 07:00 Kvartalsrapport 2025-Q1
2025-01-30 07:00 Bokslutskommuniké 2024
2024-10-17 - Kvartalsrapport 2024-Q3
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-19 - X-dag ordinarie utdelning ARJO B 0.90 SEK
2024-04-18 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-01-30 - Bokslutskommuniké 2023
2023-10-19 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-12 - Kvartalsrapport 2023-Q2
2023-04-21 - X-dag ordinarie utdelning ARJO B 0.85 SEK
2023-04-20 - Årsstämma
2023-04-20 - Kvartalsrapport 2023-Q1
2023-01-25 - Bokslutskommuniké 2022
2022-10-28 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-25 - X-dag ordinarie utdelning ARJO B 1.15 SEK
2022-04-22 - Årsstämma
2022-04-22 - Kvartalsrapport 2022-Q1
2022-02-03 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-04-28 - X-dag ordinarie utdelning ARJO B 0.85 SEK
2021-04-27 - Årsstämma
2021-04-27 - Kvartalsrapport 2021-Q1
2021-02-03 - Bokslutskommuniké 2020
2020-10-28 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-06-30 - X-dag ordinarie utdelning ARJO B 0.65 SEK
2020-06-29 - Årsstämma
2020-04-27 - Kvartalsrapport 2020-Q1
2020-02-04 - Bokslutskommuniké 2019
2019-10-22 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-08 - X-dag ordinarie utdelning ARJO B 0.55 SEK
2019-05-07 - Årsstämma
2019-05-07 - Kvartalsrapport 2019-Q1
2019-02-04 - Bokslutskommuniké 2018
2018-10-22 - Kvartalsrapport 2018-Q3
2018-07-19 - Kvartalsrapport 2018-Q2
2018-05-07 - X-dag ordinarie utdelning ARJO B 0.50 SEK
2018-05-04 - Årsstämma
2018-05-04 - Kvartalsrapport 2018-Q1
2018-01-29 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Arjo är ett globalt bolag med verksamhet inom sjukvårdsindustrin. Bolaget är idag specialiserade inom utvecklingen av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis sjukvårdssängar, golv- och taklyftar, desinfektionslösningar, samt av hygienprodukter och kompressionslösningar. Utöver erbjuds service och tillhörande tjänster samt utbildning. Störst verksamhet återfinns inom Europa och Nordamerika.
2024-04-18 14:00:00

"We start the year with growth and improved profitability. Rental and service develop well globally and the positive trend in the US continues, with a gradual improvement of the market situation. Overall, a solid start to the year and I look forward to continue the work together with the team to strengthen Arjo's positions in 2024," says Joacim Lindoff, President and CEO of Arjo.

January-March 2024 in brief
  • Net sales increased to SEK 2,759 M (2,638).
Net sales grew organically by 4.3%.
  • Adjusted EBITDA increased 5.7% to SEK 502 M (475).
  • Adjusted operating profit increased 13.2% to SEK 248 M (219).
  • Profit after financial items increased to SEK 175 M (150).
  • Earnings per share rose to SEK 0.48 (0.42).
  • Cash flow from operations rose to SEK 256 M (250), corresponding to a cash conversion of 54.2% (54.5).
  • Arjo's climate targets were approved by the Science Based Targets initiative during the quarter.

Telephone conference

Fund managers, analysts and media are invited to participate in a conference call and presentation of the report on April 18 at 15:00 CEST via the following link: https://ir.financialhearings.com/arjo-q1-report-2024

Those who wish to ask questions verbally during the teleconference will need to register via the link below. A phone number and a conference ID will be provided after registration in order to access the conference. Link to registration: https://conference.financialhearings.com/teleconference/?id=50048573

Alternatively, use the following link to download the presentation:
https://www.arjo.com/int/about-us/investors/reports--presentations/2024/

A recorded version of the conference is accessible for three years via the following link:
https://ir.financialhearings.com/arjo-q1-report-2024

For more information, please contact:

Maria Nilsson, EVP Communications & Public Relations

Tel: +46 734 244 515

Email: maria.nilsson@arjo.com 

Sara Ehinger, VP Investor Relations & Corporate Communications

Tel: +46 723 597 794

Email: sara.ehinger@arjo.com

This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on April 18, 2024.

About Arjo

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With more than 6,500 people worldwide and over 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com